Standard Preventive Interventions for Vasovagal Reactions Fail to Show Benefit in Massive 1.4 Million Donor Trial
Posted inHematology-Oncology news Public Health

Standard Preventive Interventions for Vasovagal Reactions Fail to Show Benefit in Massive 1.4 Million Donor Trial

The STRIDES trial, the largest of its kind, demonstrates that isotonic drinks, extended rest, modified muscle tension, and psychosocial support do not significantly reduce vasovagal reactions in blood donors compared to existing UK standard practices, suggesting that current safety protocols may already be optimized.
Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials
Posted inHematology-Oncology news Oncology

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap in clinical trial data quality and patient safety monitoring.
Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL
Posted inHematology-Oncology news

Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL

The CART19-BE-02 phase 2 trial demonstrates that varnimcabtagene autoleucel, utilizing a unique fractionated dose escalation strategy, achieves an 84.4% MRD-negative complete response rate in adults with relapsed or refractory B-ALL while significantly reducing the incidence of severe neurotoxicity and cytokine release syndrome.
Beyond the Count: How Product Factors and High Thresholds Shape Pediatric Platelet Transfusion Outcomes
Posted inHematology-Oncology news Pediatrics

Beyond the Count: How Product Factors and High Thresholds Shape Pediatric Platelet Transfusion Outcomes

A multicenter cohort study of 8,874 pediatric patients reveals that most prophylactic platelet transfusions occur above recommended thresholds. Factors such as pathogen reduction, additive solutions, and donor age significantly lower posttransfusion increments and increase overall transfusion burden without improving mortality or length of stay.